Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
Guidelines regarding long-term use with onabotulinumtoxinA (onaBT-A) in chronic migraine (CM) prophylaxis are lacking. This multicentric prospective real-life study aimed to assess the efficacy and safety of a long-term treatment. A total of 195 chronic migraine patients were treated with onaBT-A, e...
Main Authors: | Ilenia Corbelli, Angela Verzina, Ilaria Leone De Magistris, Gioacchino De Vanna, Paolo Eusebi, Giorgia Mataluni, Antonio Pisani, Addolorata Maria Pia Prudenzano, Maria Trojano, Marianna Delussi, Marina De Tommaso, Antonio Russo, Marcello Silvestro, Gioacchino Tedeschi, Paolo Calabresi, Paola Sarchielli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Toxins |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6651/15/1/34 |
Similar Items
-
Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine
by: Paola Sarchielli, et al.
Published: (2017-12-01) -
Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
by: Aubrey Manack Adams, et al.
Published: (2023-08-01) -
Pericranial Muscle Stiffness, Pain Thresholds, and Tenderness during a Treatment Cycle of OnabotulinumtoxinA for Chronic Migraine Prevention
by: Sebastian Worsaae Dalby, et al.
Published: (2024-02-01) -
OnabotulinumtoxinA: Still the Present for Chronic Migraine
by: Carlo Baraldi, et al.
Published: (2023-01-01) -
Botulinum Toxin in the Treatment of Headache
by: Werner J. Becker
Published: (2020-12-01)